Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 16, 2023
Initiated Phase 2 expansion of darovasertib and crizotinib combination in GNAQ/11 metastatic cutaneous melanoma based on preliminary clinical efficacy observed Approximately 5% of cutaneous...
-
Oct 9, 2023
Selected a Werner Helicase Inhibitor Development Candidate in collaboration with GSK Observed monotherapy complete responses preclinically in multiple in vivo xenograft MSI-High models and...
-
Oct 6, 2023
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on September 28, 2023, the...
-
Sep 27, 2023
Fast Track designation granted by U.S. FDA for evaluation of IDE161 in adult patients with HR+, Her2-, BRCA1/2 mutant advanced or metastatic breast cancer patients who have been pretreated with...
-
Sep 26, 2023
Fast Track designation granted by U.S. FDA for evaluation of IDE161 in adult patients with BRCA1/2 mutant advanced or metastatic ovarian cancer who are platinum resistant and have received prior...
